Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control

References

• Doi Y, Bonomo RA, Hooper DC, et al. Gram-negative committee of the antibacterial resistance leadership group (ARLG). Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis. 2017;64(suppl_1):S30–S35.
   PubMed Web of Science ®Google Scholar
• De Waele JJ, Akova M, Antonelli M, et al. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Med. 2018 Feb;44(2):189–196. Epub 2017 Dec 29. PubMed PMID: 29288367.
   PubMed Web of Science ®Google Scholar
• Grundmann H, Glasner C, Albiger B, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–163.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Poulakou G, Ruppe E, et al. Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 2017;43:1464–1475.
   PubMed Web of Science ®Google Scholar
• [cited 2018 Apr 15]. Available from https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5810a4.htm
   Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. ISGRI-SITA (Italian study group on resistant infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–2143.
   PubMed Web of Science ®Google Scholar
• Bassetti M, De Waele JJ, Eggimann P, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015;41:776–795.
   PubMed Web of Science ®Google Scholar
• Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017;17(1):203.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Cataldo MA, Dancer SJ, et al. European Society of Clinical Microbiology. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(Suppl 1):1–55.
   PubMed Web of Science ®Google Scholar
• Gagliotti C, Ciccarese V, Sarti M, et al. Active surveillance for asymptomatic carriers of carbapenemase-producing Klebsiella pneumoniae in a hospital setting. J Hosp Infect. 2013;83(4):330–332.
   PubMed Web of Science ®Google Scholar
• Snyder GM, D’Agata EM. Diagnostic accuracy of surveillance cultures to detect gastrointestinal colonization with multidrug-resistant gram-negative bacteria. Am J Infect Control. 2012;40(5):474–476.
   PubMed Web of Science ®Google Scholar
• Kim YK, Song SA, Lee JN, et al. Clinical factors predicting persistent carriage of Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae among patients with known carriage. J Hosp Infect. 2018;99:405-412.
   Google Scholar
• Kim YK, Feldman N, Adler A, et al. Gastrointestinal colonization by KPC-producing Klebsiella pneumoniae following hospital discharge: duration of carriage and risk factors for persistent carriage. Clin Microbiol Infect. 2013;19(4):E190–E196.
   PubMed Web of Science ®Google Scholar
• Borgmann S, Pfeifer Y, Becker L, et al. Findings from an outbreak of carbapenem-resistant Klebsiella pneumoniae emphasize the role of antibiotic treatment for cross transmission. Infection. 2018;46(1):103–112.
   PubMed Web of Science ®Google Scholar
• Cubero M, Cuervo G, Dominguez MÁ, et al. Carbapenem-resistant and carbapenem-susceptible isogenic isolates of Klebsiella pneumoniae ST101 causing infection in a tertiary hospital. BMC Microbiol. 2015;15:177.
   PubMed Web of Science ®Google Scholar
• Zarakolu P, Eser OK, Aladag E, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: a surveillance study at a Turkish university hospital from 2009 to 2013. Diagn Microbiol Infect Dis. 2016;85:466–470.
   PubMed Web of Science ®Google Scholar
• Armand-Lefèvre L, Angebault C, Barbier F, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013;57:1488–1495.
   PubMed Web of Science ®Google Scholar
• Gharbi M, Moore LS, Gilchrist M, et al. Forecasting carbapenem resistance from antimicrobial consumption surveillance: lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit. Int J Antimicrob Agents. 2015;46:150–156.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Lin MY, Haverkate M, et al. Modifiable risk factors for the spread of Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae among long-term acute-care hospital Patients. Infect Control Hosp Epidemiol. 2017;38(6):670–677.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Tumietto F, et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2014;58(6):3514–3520.
   PubMed Web of Science ®Google Scholar
• Demiraslan H, Cevahir F, Berk E, et al. Is surveillance for colonization of carbapenem-resistant gram-negative bacteria important in adult bone marrow transplantation units? Am J Infect Control. 2017;45(7):735–739.
   PubMed Web of Science ®Google Scholar
• Cronin KM, Poy Lorenzo YS, Olenski ME, et al. Risk factors for KPC-producing Enterobacteriaceae acquisition and infection in a healthcare setting with possible local transmission: a case-control study. J Hosp Infect. 2017;96(2):111–115.
   PubMed Web of Science ®Google Scholar
• Chiotos K, Tamma PD, Flett KB, et al. Multicenter study of the risk factors for colonization or infection with carbapenem-resistant enterobacteriaceae in children. Antimicrob Agents Chemother. 2017;61(12):pii: e01440–e01517.
   PubMed Web of Science ®Google Scholar
• Madueño A, González García J, Ramos MJ, et al. Risk factors associated with carbapenemase-producing Klebsiella pneumoniae fecal carriage: a case-control study in a Spanish tertiary care hospital. Am J Infect Control. 2017;45(1):77–79.
   PubMed Web of Science ®Google Scholar
• Muggeo A, Guillard T, Barbe C, et al. CARBAFREST Group. Factors Associated with carriage of carbapenem-non-susceptible Enterobacteriaceaein North-Eastern France and Outcomes of Infected Patients. J Antimicrob Chemother. 2017;72(5):1496–1501.
   PubMed Web of Science ®Google Scholar
• Giufrè M, Ricchizzi E, Accogli M, et al. Colonization by multidrug-resistant organisms in long-term care facilities in Italy: a point-prevalence study. Clin Microbiol Infect. 2017;23(12):961–967.
   PubMed Web of Science ®Google Scholar
• Lübbert C, Becker-Rux D, Rodloff AC, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. 2014;42(2):309–316.
   PubMed Web of Science ®Google Scholar
• Kim S, Russell D, Mohamadnejad M, et al. Risk factors associated with the transmission of carbapenem-resistant enterobacteriaceae via contaminated duodenoscopes. Gastrointest Endosc. 2016;83(6):1121–1129.
   PubMed Web of Science ®Google Scholar
• Chapman CG, Siddiqui UD, Manzano M, et al. Risk of infection transmission in curvilinear array echoendoscopes: results of a prospective reprocessing and culture registry. Gastrointest Endosc. 2017;85(2):390–397.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Yang S, Kim S, et al. Duodenoscope-related outbreak of a carbapenem-resistant Klebsiella pneumoniae identified using advanced molecular diagnostics. Clin Infect Dis. 2017;65(7):1159–1166.
   PubMed Web of Science ®Google Scholar
• Gastmeier P, Vonberg RP. Klebsiella spp. in endoscopy-associated infections: we may only be seeing the tip of the iceberg. Infection. 2014;42(1):15–21.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Are BM, Pesapane L, et al. Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study. J Hosp Infect. 2018;99:413-418.
   Google Scholar
• Liu P, Papadimitrou, Wang Z, Huang L, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection and mortality of Klebsiella pneumoniae infection. Chin Med J (Engl). 2018;131(1):56–62.
   PubMed Web of Science ®Google Scholar
• Gorrie CL, Mirceta M, Wick RR, et al. Gastrointestinal carriage is a major reservoir of Klebsiella pneumoniae infection in intensive care patients. Clin Infect Dis. 2017;65(2):208–215.
   PubMed Web of Science ®Google Scholar
• Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect. 2014;20(12):1357–1362.
   PubMed Web of Science ®Google Scholar
• Tascini C, Urbani L, Sbrana F, et al. Oral administration of gentamicin for prophylaxis of KPC-producing Klebsiella pneumoniae gut colonization in patients treated with a novel parenchymal-sparing liver surgery: the GEN Gut study. Intensive Care Med. 2016;42(1):124–125.
   PubMed Web of Science ®Google Scholar
• Tascini C, Sbrana F, Flammini S, et al. GENGUT study group. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy. Antimicrob Agents Chemother. 2014;58(4):1972–1976.
   PubMed Web of Science ®Google Scholar
• Lambelet P, Tascini C, Fortunato S, et al. Oral gentamicin therapy for carbapenem-resistant Klebsiella pneumoniae gut colonization in hematologic patients: a single center experience. New Microbiol. 2017;40(3):161–164.
   PubMed Web of Science ®Google Scholar
• Machuca I, Gutiérrez-Gutiérrez B, Pérez Cortés S, et al. Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2016;71(11):3242–3249.
   PubMed Web of Science ®Google Scholar
• Saidel-Odes L, Polachek H, Peled N, et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol. 2012;33(1):14–19.
   PubMed Web of Science ®Google Scholar
• Lübbert C, Faucheux S, Becker-Rux D, et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae: a single-centre experience. Int J Antimicrob Agents. 2013;42(6):565–570.
   PubMed Web of Science ®Google Scholar
• Strenger V, Gschliesser T, Grisold A, et al. Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum β-lactamase-producing enterobacteria in hospitalised newborns. Int J Antimicrob Agents. 2011;37(1):67–69.
   PubMed Web of Science ®Google Scholar
• Li X, Luo M, Xu X, et al. Risk Factors for carbapenem-resistant Klebsiella pneumoniae Infection: a meta-analysis. Microb Drug Resist. 2018;24(2):190–198.
   PubMed Web of Science ®Google Scholar
• Giannella M, Graziano E, Marconi L, et al. Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study. Eur J Clin Microbiol Infect Dis. 2017;36(10):1965–1970.
   PubMed Web of Science ®Google Scholar
• Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11:589–603.
   PubMed Web of Science ®Google Scholar
• [cited 2018 Apr 15]. Available from https://www.ncbi.nlm.nih.gov/books/NBK144014
   Google Scholar
• Fournier S, Desenfant L, Monteil C, et al. The Ap-Hp outbreaks control group. Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015. Euro Surveill. 2018;23(8).
   PubMedGoogle Scholar
• Kotsanas D, Wijesooriya WR, Korman TM, et al. “Down the drain”: carbapenem-resistant bacteria in intensive care unit patients and handwashing sinks. Med J Aust. 2013;198(5):267–269.
   PubMed Web of Science ®Google Scholar
• Chrysou K, Zarkotou O, Kalofolia S, et al. First-year results of an antibiotic stewardship program in a Greek tertiary care hospital. Eur J Clin Microbiol Infect Dis. 2018;37(2):333–337.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Del Bono V, Mikulska M, et al. San Martino Antimicrobial Stewardship Group. Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. Infection. 2017;45(6):849–856. Erratum in: Infection. 2017 Dec;45(6):929.
   PubMed Web of Science ®Google Scholar
• Viale P, Giannella M, Bartoletti M, et al. Considerations about antimicrobial stewardship in settings with epidemic extended-spectrum β-Lactamase-producing or carbapenem-resistant Enterobacteriaceae. Infect Dis Ther. 2015;4(Suppl 1):65–83.
   PubMedGoogle Scholar
• Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016;29:583–594.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Peghin M, Carnelutti A, et al. How should we treat HAP/VAP caused by carbapenemase-producing Enterobacteriaceae? Semin Respir Crit Care Med. 2017;38:301–310.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Rogers BA. How soon is now? The urgent need for randomized, controlled trials evaluating treatment of multidrug-resistant bacterial infection. Clin Infect Dis. 2010;51:1245–1247.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391–400.
   PubMed Web of Science ®Google Scholar
• NCT01597973
   Google Scholar
• Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20:862–872.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–2328.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–950.
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798–1803.
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–2113.
   PubMed Web of Science ®Google Scholar
• Pea F, Della Siega P, Cojutti P, et al. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents. 2017;49:255e8.
   Web of Science ®Google Scholar
• Morrill HJ, Pogue JM, Kaye KS, et al. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis. 2015;2:ofv050.
   PubMed Web of Science ®Google Scholar
• Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69:2305–2309.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Giannella M, Lewis RE, et al. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11:159–177.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17:726–734.
   PubMed Web of Science ®Google Scholar
• Falcone M, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect. 2016;22:444–450.
   PubMed Web of Science ®Google Scholar
• Ceccarelli G, Falcone M, Giordano A, et al. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013;57:2900–2901.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2017. DOI:10.1016/j.cmi.2017.08.030
   Web of Science ®Google Scholar
• De Oliveira MS, de Assis DB, Freire MP, et al. Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. Clin Microb Infect. 2015;21:179.e1e7.
   Google Scholar
• Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6:26.
   PubMed Web of Science ®Google Scholar
• Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2013;20:117–123.
   PubMed Web of Science ®Google Scholar
• Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem- resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19:E23–E30.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Del Bono V, Trecarichi EM, et al. Risk factors for bloodstream infections due to colistin-resistant KPC- producing Klebsiella pneumoniae: results from a multicenter case-control- control study. Clin Microbiol Infect. 2015;21:1106.e1–8.
   Web of Science ®Google Scholar
• Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–168.
   PubMed Web of Science ®Google Scholar
• Mendes AC, Novais Â, Campos J, et al. mcr-1 in carbapenemase-producing Klebsiella pneumoniae with hospitalized patients, Portugal, 2016-2017. Emerg Infect Dis. 2018;24:762–766.
   PubMed Web of Science ®Google Scholar
• Mediavilla JR, Patrawalla A, Chen L, et al. Colistin- and carbapenem-resistant Escherichia coli Harboring mcr-1 and blaNDM-5, causing a complicated urinary tract infection in a patient from the United States. Mbio. 2016;7:4.
   Web of Science ®Google Scholar
• Li Y, Sun QL, Shen Y, et al. Rapid increase in prevalence of carbapenem-resistant Enterobacteriaceae (CRE) and emergence of colistin resistance gene mcr-1 in CRE in a hospital in Henan, China. J Clin Microbiol. 2018;56:4.
   Web of Science ®Google Scholar
• De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18:R90.
   PubMed Web of Science ®Google Scholar
• Cunha BA. Pharmacokinetic consideration regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol. 2009;47:1613.
   Web of Science ®Google Scholar
• Spanu T, De Angelis G, Cipriani M, et al. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2012;56:4516–4518.
   PubMed Web of Science ®Google Scholar
• Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009;49:271–274
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005;41:S333–S340.
   PubMed Web of Science ®Google Scholar
• MSatlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin b, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55:5893–5899.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70:905–913.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35:240–243.
   PubMed Web of Science ®Google Scholar
• Yu W, Shen P, Bao Z, et al. In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2017;50:237–241.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31:2.
   Web of Science ®Google Scholar
• Murri R, Fiori B, Spanu T, et al. Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series. Infection. 2017;45:209–213.
   PubMed Web of Science ®Google Scholar
• Fredborg M, Sondergaard TE, Wang M. Synergistic activities of meropenem double and triple combinations against carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2017;88:355–360.
   PubMed Web of Science ®Google Scholar
• Harris PN, Tambyah PA, Paterson DL, et al. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?. Lancet Infect Dis. 2015;15:475–485.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73:159–177.
   PubMed Web of Science ®Google Scholar
• Jayol A, Nordmann P, Poirel L, et al. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73:542–544.
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661–673.
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–295.
   PubMed Web of Science ®Google Scholar
• Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61:2.
   Web of Science ®Google Scholar
• Gugliandolo A, Caio C, Mezzatesta ML, et al. Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: a case report. Medicine (Baltimore). 2017;96:e7664.
   PubMed Web of Science ®Google Scholar
• García-Castillo M, García-Fernández S, Gómez-Gil R, et al. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain. Int J Antimicrob Agents. 2018;51:511–515.
   PubMed Web of Science ®Google Scholar
• Gaibani P, Lewis RE, Volpe SL, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis. 2017;65:1–3.
   PubMed Web of Science ®Google Scholar
• Shields RK, Chen L, Cheng S, et al. Emergence of Ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61:3.
   Web of Science ®Google Scholar
• Humphries RM, Yang S, Hemarajata P, et al. First report of Ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother. 2015;59:6605–6607.
   PubMed Web of Science ®Google Scholar
• Jacobs DM, DiTursi S, Ruh C, et al. Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient. Int J Antimicrob Agents. 2016;48:225–227.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Lomovskaya O, Dudley MN, et al. In vitro activity of Meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62:1.
   Web of Science ®Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61:12.
   Web of Science ®Google Scholar
• Lee YR, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis. 2018 Apr 19. DOI:10.1007/s10096-018-3260-4
   Web of Science ®Google Scholar
• Kaye KS, Bhowmick T, Metallidis S, et al. Effect of Meropenem-vaborbactam vs Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788–799.
   PubMed Web of Science ®Google Scholar
• [cited 2018 May 20]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209776lbl.pdf
   Google Scholar
• TANGO II NCT02168946
   Google Scholar
• TANGO III NCT03006679
   Google Scholar
• Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68:2286–2290.
   PubMed Web of Science ®Google Scholar
• Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of Imipenem with relebactam against Gram-negative pathogens from New York City. Antimicrob Agents Chemother. 2015;59:5029–5031.
   PubMed Web of Science ®Google Scholar
• NCT02452047
   Google Scholar
• NCT02493764
   Google Scholar
• López Díaz MC, Ríos E, Rodríguez-Avial I, et al. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents. Int J Antimicrob Agents. 2017;50:191–196.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Avial I, Pena I, Picazo JJ, et al. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents. 2015;46:616–621.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kashikar A, Bush K. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE). J Antimicrob Chemother. 2017;72:2792–2795.
   PubMed Web of Science ®Google Scholar
• Denervaud-Tendon V, Poirel L, Connolly L, et al. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates. J Antimicrob Chemother.2017. 72:2787–2791.
   Google Scholar
• Portsmouth S, Van Veenhuyzen D, Echols R, et al. Clinical response of cefiderocol compared with imipenem/cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: results from a multicenter, double blind, randomized study (APEKS-cUTI). Open Forum Infect Dis. 2017;4:S537–S538.
   Google Scholar
• NCT03032380
   Google Scholar
• NCT02714595
   Google Scholar
• NCT01689207
   Google Scholar
• NCT02655419
   Google Scholar
• NCT03329092
   Google Scholar
• Abdallah M, Olafisoye O, Cortes C, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59:1802–1805.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Baxter MR, Adam HJ, et al. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015. Diagn Microbiol Infect Dis. 2018;91:55–62.
   PubMed Web of Science ®Google Scholar
• Snydman DR, McDermott LA, Jacobus NV, et al. Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2018;62(5).
   PubMed Web of Science ®Google Scholar
• Sutcliffe JA, O’Brien W, Fyfe C, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57:5548–5558.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E. Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs. 2014;23:1575–1584.
   PubMed Web of Science ®Google Scholar
• Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg. 2017;152:224–232.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Sader HS, Farrell DJ, et al. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob Agents Chemother. 2012;56:4779–4785.
   PubMed Web of Science ®Google Scholar
• NCT01281462
   Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother. 2017 May;72(5):1373–1385.
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Flamm RK, et al. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother. 2017 Jun 1;72(6):1696–1703.
   PubMed Web of Science ®Google Scholar
• NCT02674347
   Google Scholar
• NCT02532140
   Google Scholar
• NCT02707107
   Google Scholar
• NCT02942810
   Google Scholar
• Livermore DM, Warner M, Mushtaq S, et al. Interactions of OP0595, a novel triple-action Diazabicyclooctane, with β-Lactams against OP0595-resistant enterobacteriaceae mutants. Antimicrob Agents Chemother. 2015 Nov 9;60(1):554–560. Print 2016 Jan.
   PubMed Web of Science ®Google Scholar
• Morinaka A, Tsutsumi Y, Yamada K, et al. In vitro and in vivo activities of OP0595, a new diazabicyclooctane, against CTX-M-15-positive escherichia coli and KPC-positive Klebsiella pneumoniae. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3001–3006.
   PubMed Web of Science ®Google Scholar
• Morrissey I, Magnet S, Hawser S, et al. In vitro activity of Nacubactam, a novel dual action diazabicyclooctane, alone and with meropenem, against beta-lactamase-positive Enterobacteriaceae, P1039 presented at ECCMID 2018. Madrid, Spain; 2018 April 21–24.
   Google Scholar
• NCT03182504
   Google Scholar
• Durand-Réville TF, Guler S, Comita-Prevoir J, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol. 2017;2:17104.
   PubMed Web of Science ®Google Scholar
• NCT03445195
   Google Scholar
• Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. New Engl J Med. 2013;368:407–415.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835–843.
   PubMed Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:987–994.
   PubMed Web of Science ®Google Scholar
• [cited 2018 May 08]. Available from https://www.openbiome.org
   Google Scholar
• Hirsch BE, Saraiya N, Poeth K, et al. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis. 2015;15:191.
   PubMed Web of Science ®Google Scholar
• Rubin TA, Gessert CE, Aas J, et al. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe. 2013;19:22–26.
   PubMed Web of Science ®Google Scholar
• Patel NC, Griesbach CL, DiBaise JK, et al. Fecal microbiota transplant for recurrent Clostridium difficile infection: mayo clinic in Arizona experience. Mayo Clin Proc. 2013;88:799–805.
   PubMed Web of Science ®Google Scholar
• Ganc AJ, Ganc RL, Reimão SM, et al. Fecal microbiota transplant by push enteroscopy to treat diarrhea caused by Clostridium difficile. Einstein (Sao Paulo). 2015;13:338–339.
   PubMed Web of Science ®Google Scholar
• Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315:142–149.
   PubMed Web of Science ®Google Scholar
• Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772–1778.
   PubMed Web of Science ®Google Scholar
• Singh R, de Groot PF, Geerlings SE, et al. Fecal microbiota transplantation against intestinal colonization by extended spectrum beta-lactamase producing Enterobacteriaceae: a proof of principle study. BMC Res Notes. 2018;11:190.
   PubMedGoogle Scholar
• NCT02312986
   Google Scholar
• Bilinski J, Grzesiowski P, Sorensen N, et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin Infect Dis. 2017;65:364–370.
   PubMed Web of Science ®Google Scholar
• Lagier JC, Million M, Fournier PE, et al. Faecal microbiota transplantation for stool decolonization of OXA-48 carbapenemase-producing Klebsiella pneumoniae. J Hosp Infect. 2015;90:173–174.
   PubMed Web of Science ®Google Scholar
• Freedman A, Eppes S. Use of stool transplant to clear fecal colonization with carbapenem-resistant Enterobacteriaceae (CRE): proof of concept. Id Week. 2014;session:227.
   Google Scholar
• Pea F, Della Siega P, Cojutti P, et al. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents. 2017;49:255–258.
   PubMed Web of Science ®Google Scholar
• Cojutti P, Sartor A, Righi E, et al. Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(10).
   Web of Science ®Google Scholar
• Poirel L, Walsh TR, Cuvillier V, et al. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70:119–123.
   PubMed Web of Science ®Google Scholar
• Monteiro J, Widen RH, Pignatari AC, et al. Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother. 2012;67:906–909.
   PubMed Web of Science ®Google Scholar